Get started
Work

Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

Year: 2019
Type: article
DOI: 10.1093/annonc/mdz255.007
Authors: D. Rischin, A.M. Lim, C.D. Schmults, N.I. Khushalani, B.G. Hughes, D. Schadendorf, L.A. Dunn, A.L.S. Chang, A. Hauschild, C. Ulrich, T. Eigentler, M.R. Migden, A.C. Pavlick, J. Geiger, E. Stankevich, S. Li, I. Lowy, M.G. Fury, A. Guminski
Institutions: Peter MacCallum Cancer Centre, Sir Charles Gairdner Hospital, Brigham and Women's Hospital, Harvard University, Moffitt Cancer Center, The University of Queensland, Royal Brisbane and Women's Hospital, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, Memorial Sloan Kettering Cancer Center, Stanford Medicine, Stanford University, University Hospital Schleswig-Holstein, Charité – Universitätsmedizin Berlin, Universitätsklinikum Tübingen, University of Tübingen, The University of Texas MD Anderson Cancer Center, NYU Langone Health, Cleveland Clinic, Regeneron (United States), Royal North Shore Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2978968117
FWCI: 1.321
Cites:
Cited by: 9
Related to: 10